Supernus to Announce Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021
A live webcast will be available at www.supernus.com.
Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.
|Conference dial-in:||(877) 288-1043|
|International dial-in:||(970) 315-0267|
|Conference Call Name:||Supernus Pharmaceuticals Third Quarter 2021 Results Conference Call|
Following the live call, a replay will be available on the Company’s website, www.supernus.com, in the Investor Relations section. The webcast will be available on the Company’s website for 60 days following the live call.
Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease, cervical dystonia and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in Parkinson’s disease, epilepsy, depression and rare CNS disorders.
For more information, please visit www.supernus.com.
Tel: (301) 838-2591
Office: (443) 213-0505
Mobile: (443) 377-4767
Source: Supernus Pharmaceuticals, Inc.